Researchers have determined that inhibiting the oligomerization of β-arrestin-2 suppresses tau protein accumulation in a mouse model of dementia.
An initial analysis of the international Phase II/III trial (DIAN-TU) evaluating solanezumab and gantenerumab in people in the early stages of a rare and inherited form of Alzheimer’s disease has yielded disappointing results.
English and Italian speakers who have dementia-related language impairments may experience distinctive speech and reading difficulties based on features of their native languages.
A common mutation in a key enzyme involved in alcohol metabolism may increase damage in cells obtained from individuals with Alzheimer’s disease and in mice.
At the Clinical Trials on Alzheimer’s Disease Congress this week, Biogen (MA, USA) has provided a detailed report on the latest aducanumab results, including why there was such a difference in the results between ENGAGE and EMERGE.
A recent set of studies reports how blood–brain barrier leakage may affect inflammation in the brain, potentially leading to acceleration of neurological aging in mice.
Sex-specific effects of microbiome perturbations in an Alzheimer’s mouse model: an interview with Hemraj Dodiya
At SfN Neuroscience 2019, we had the brilliant opportunity of interviewing Hemraj Dodiya about sex-specific effects of microbiome perturbations in an Alzheimer’s mouse model.
Preclinical data has demonstrated that an oral small molecule drug could inhibit the formation of neurotoxic tau oligomers in an animal model most relevant to Alzheimer’s disease.
What are the challenges associated with identifying risk genes for Alzheimer’s disease? What more needs to be done to successfully translate this genetic data into potential therapeutics? Watch our video with Owen Peters to find out more.
What might the mechanisms behind circadian dysfunction in the early stages of dementia be? What more needs to be done to successfully translate this into the clinic? Watch our video with Marco Brancaccio to find out.